China
Africa
Explore chapters and articles related to this topic
Mammography and Interventional Breast Procedures
Published in Raymond Taillefer, Iraj Khalkhali, Alan D. Waxman, Hans J. Biersack, Radionuclide Imaging of the Breast, 2021
Circumscribed carcinoma is a descriptive term referring to any ductal carcinoma that appears as a circumscribed mass with well-defined margin and no spiculation [31]. Circumscribed carcinoma includes all medullary [41], papillary [42], and mucinous carcinoma as well as some invasive ductal carcinoma [43] and some in situ ductal carcinoma [44]. Uncommonly, invasive lobular carcinoma can present as a circumscribed mass [31]. The likelihood of malignancy for a completely well-defined circumscribed mass of 1 cm or less is extremely low [31]. If these well-defined circumscribed masses are >1 cm, palpable or nonpalpable, the chance of cancer is 2% [45,46].
Oncologic considerations
Published in Steven J. Kronowitz, John R. Benson, Maurizio B. Nava, Oncoplastic and Reconstructive Management of the Breast, 2020
Steven J. Kronowitz, John R. Benson, Maurizio B. Nava
These studies concluded that diagnosis of invasive lobular carcinoma is not a contraindication for breast-conserving therapy. Treatment options for both lobular and ductal breast cancers should be similar and histologic subtype is not a significant independent predictor of recurrence or survival.53–56 Rates of re-excision to achieve negative margins appear to be higher for the lobular subtype; nonetheless, these patients are considered candidates for breast-conserving therapy if the tumor is not diffusely present throughout the breast and the lesion can be excised with tumor-free margins.
The breasts
Published in C. Simon Herrington, Muir's Textbook of Pathology, 2020
Invasive lobular carcinoma (Figure 16.18) accounts for approximately 10%–15% of all invasive breast carcinomas, but various sub-types are recognized, including classical, alveolar, solid, pleomorphic and tubulo-lobular forms; mixed patterns may also be seen.
Neoadjuvant immune checkpoint blockade triggers persistent and systemic Treg activation which blunts therapeutic efficacy against metastatic spread of breast tumors
Published in OncoImmunology, 2023
Olga S. Blomberg, Kevin Kos, Lorenzo Spagnuolo, Olga I. Isaeva, Hannah Garner, Max D. Wellenstein, Noor Bakker, Danique E.M. Duits, Kelly Kersten, Sjoerd Klarenbeek, Cheei-Sing Hau, Daphne Kaldenbach, Elisabeth A.M. Raeven, Kim Vrijland, Marleen Kok, Karin E. de Visser
We validated our findings in the Wap-cre;Cdh1F/F;AktE17K;Trp53KO (WEAP) tumor cell inoculation model of invasive lobular carcinoma42,43. Like in KEP tumors, the frequency of PD-1 and CTLA-4 expression was higher on intratumoral Tregs compared to CD8+ T cells (figure S1H). aPD-1/CTLA-4 treatment led to a modest survival benefit in mice bearing WEAP tumors (figure S1I). We found an increase in FOXP3 counts in WEAP tumors upon ICB, but interestingly also an increase in CD8 counts (figure S1J), potentially explaining the response to ICB in WEAP tumor-bearing mice which was not observed in KEP mice. Together, these data show that increased Treg infiltration by ICB is observed in two independent breast cancer models.
Expression of CDK13 Was Associated with Prognosis and Expression of HIF-1α and beclin1 in Breast Cancer Patients
Published in Journal of Investigative Surgery, 2022
Xia-Liang Lu, Rui Zhan, Guang-Ming Zhao, Zhen-Hua Qian, Chan-Chan Gong, Yan-Qing Li
First, we compared the expression of CDK13, HIF-1α and beclin1 in 189 paired of breast cancer tissues and paracancerous non-tumor tissues. As shown in Table 1, the mean age of all patients was 51.98 ± 13.01, with BMI 23.39 ± 2.60. A total of 91 (48.15%) cases were with TNM stage I–II and 98 (51.85%) cases were with TNM stages III–IV. Invasive ductal carcinoma was found in 103 (54.50%) cases, while invasive lobular carcinoma was found in 86 (45.50%) cases. Meanwhile, luminal A type was found in 61 (32.27%) cases, luminal B type was found in 43 (22.75) cases, HER2 positive type was in 56 (29.63%) and 29 (15.34%) cases were with triple-negative breast cancer (TNBC). The expression levels of CDK13 were found as high expression (IHC score > 3) in 132 (69.84%) cases, and low expression in 58 (30.69%) cases, while 122 (64.55%) cases were with high expression (IHC score > 3) of HIF-1α and 46 (24.34%) cases were with high expression (IHC score > 3) of beclin1. The mean IHC scores of both CDK13 and HIF-1α in tumor tissues (CDK13 4.26 ± 2.07 and HIF-1α 4.15 ± 2.12) were remarkably higher, while beclin1 (2.60 ± 2.07) was markedly lower than in the paracancerous non-tumor tissues (CDK13 1.41 ± 1.14, HIF-1α 1.61 ± 1.15 and beclin1 5.41 ± 1.18) (P < 0.05, Figure 1).
The Wnt/β-catenin pathway in breast cancer therapy: a pre-clinical perspective of its targeting for clinical translation
Published in Expert Review of Anticancer Therapy, 2022
Dezaree Raut, Amisha Vora, Lokesh Kumar Bhatt
An essential component of the Wnt signaling pathway, β-catenin can function as an oncogene after translocation into the nucleus. It causes the transactivation of target genes by binding to TCF or members of LEF [23]. The two most common histological subtypes of breast cancer are invasive ductal carcinoma no-special-type (IDC-NST) and invasive lobular carcinoma (ILC). IDCs have a regular pattern of β-Catenin expression, with membranous expression and nuclear expression (80.6% and 12.5%), respectively. ILCs, on the other hand, lack membranous expression (14.7%) and no nuclear expression. Also, β-catenin and E-cadherin are expressions is preserved in ductal carcinoma and show a loss in lobular carcinoma. Hence, IDC has a worse prognosis than the ILC subtype of breast carcinoma [21].